Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads
- 14 August 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 20494-20519
Abstract
Drugs targeting Bruton’s tyrosine kinase (BTK) are recognized as key tools in hematological oncology. The clinical efficacy of BTK inhibitors is limited, however, by the emerging resistance driven by BTK mutations and the severe toxicity attributed to off-target kinase inhibition. PROteolysis TArgeting Chimeras (PROTACs) offer an alternative modality to address these major drawbacks. Herein, we present novel BTK-targeting PROTACs with a high potency against both the wild-type and the mutated BTK. Novel CRBN-binding warheads have been developed to mitigate the off-target protein degradation associated with anchors derived from thalidomide analogues. The linker optimization effort resulted in a series of potent, orally bioavailable BTK-targeting PROTACs without concomitant activity against IKZF1, IKZF3, and GSPT1. The lead compounds ISM-PR25 and ISM-PR44 demonstrate sufficient efficacy in degrading BTK protein in malignant B cells (DC50 = 0.04 and 0.05 nM, respectively) associated with a favorable DMPK profile and a large safety window regarding cell toxicity and effectively degraded BTK in mouse circulating B cells by single-dose oral treatment (3 mg/kg).Keywords
This publication has 39 references indexed in Scilit:
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatmentCancer, 2025
- Discovery of TQ-3959 as a Potent and Orally Bioavailable BTK PROTAC Degrader Incorporating a Novel Benzisoxazole-Based CRBN Ligand for the Treatment of B-Cell MalignanciesJournal of Medicinal Chemistry, 2025
- Identification of Novel pan-KRAS Inhibitors via Structure-Based Drug Design, Scaffold Hopping, and Biological EvaluationACS Medicinal Chemistry Letters, 2025
- Design, synthesis, and biological evaluation of novel BTK-targeting proteolysis targeting chimeras (PROTACs) with enhanced pharmacokinetic propertiesEuropean Journal of Medicinal Chemistry, 2025
- Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell MalignanciesJournal of Medicinal Chemistry, 2024
- Discovery of Novel Bruton’s Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular EfficacyJournal of Medicinal Chemistry, 2023
- Chemistry42: An AI-Driven Platform for Molecular Design and OptimizationJournal of Chemical Information and Modeling, 2023
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated DegradationBiochemistry, 2018
- Ibrutinib: First Global ApprovalDrugs, 2014
- The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stagesEuropean Journal of Immunology, 1993